Drugs that contain Talazoparib Tosylate
1. Drug name - TALZENNA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8420650 | PFIZER | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
Jul, 2029
(6 years from now) | |
| US8012976 | PFIZER | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
Oct, 2029
(7 years from now) | |
| US10189837 | PFIZER | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt |
Oct, 2031
(9 years from now) | |
| US8735392 | PFIZER | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt |
Oct, 2031
(9 years from now) | |
| CN104478875A | PFIZER | Dihydro Pyridine Phthalocyanine Triazine Ketone Inhibitor Of Poly (Adp-Ribose) Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| CN102171214A | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| CN102171214B | PFIZER | Poly (Adp-Ribose) Polymerase (Parp) And Dihydro Pyridine Phthalocyanine And Triazine Ketone Inhibitor |
Jul, 2029
(6 years from now) | |
| CN104478875B | PFIZER | Poly (Adp-Ribose) Polymerase (Parp) Dihydropyridine And Phthalazinone Inhibitors |
Jul, 2029
(6 years from now) | |
| CN103282365B | PFIZER | Crystalline Toluenesulfonate Of (8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phthalazine-3-(7H)-One |
Oct, 2031
(9 years from now) | |
| CN103282365A | PFIZER | Crystals Of (8S, 9R) -5-(4 - (-8 - Fluorophenyl) -9-(1-Methyl - -1H-1, 2, 4-Triazole - -5 - Group) - 9, -8 - Dihydro - -2H - Pyrido [4 3, 2-De] Phthalazine -3 (7H) - Ketone Tosylate |
Oct, 2031
(9 years from now) | |
| IN298469B | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adpribose) Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| EP2326650B9 | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| EP2326650A4 | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| EP2326650A2 | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| EP2326650B1 | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| EP2767537B1 | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| EP2767537A1 | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| EP2630146B1 | PFIZER | Crystaline (8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phtalazin-3(7H)-One Tosylate Salt |
Oct, 2031
(9 years from now) | |
| EP2630146A1 | PFIZER | Crystaline (8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phtalazin-3(7H)-One Tosylate Salt |
Oct, 2031
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9820985 | PFIZER | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
Jul, 2029
(6 years from now) | |
Treatment: Treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (brca)-mutated (gbrcam) human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer
Dosage: CAPSULE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.25MG BASE | CAPSULE;ORAL | Prescription |
| EQ 0.5MG BASE | CAPSULE;ORAL | Prescription |
| EQ 0.75MG BASE | CAPSULE;ORAL | Prescription |
| EQ 1MG BASE | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.